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Abstract
Introduction: Radioactive iodine (131I) is widely prescribed for treatment of Graves’ disease. A dose
of 370 to 555 MBq (10 to 15 mCi) is usually enough, but reports of improved remission rates with
single doses up to 20-30 mCi, and 38.5 mCi at most, exist.
Case presentation: A 53-year-old male patient was evaluated in September 2005, with symptoms
of thyrotoxicosis for 2 years. He presented with tachycardia (130 bpm) and a large goiter.
Thyrotropin was <0.01 uIU/ml (0,41-4,5), free thyroxin >7.77 ng/dl (0.9-1.8), anti-thyreoperoxidase
antibody: 374 IU/ml (<35) and anti-thyroglobulin antibody: 749 IU/ml (<115). Ultrasound: diffuse
goiter, no nodules; right lobe: 7.9 × 3.8 × 3.8 cm; left: 7.7 × 3.5 × 3.8 cm; isthmus: 1.6 cm.
Propylthiouracil 300 mg t.i.d. and propranolol were prescribed. Thyroid 99mTc-pertechnetate uptake:
52% (0.35-1.7%) and estimated thyroid volume: 149 mL. After 30 days, he received 555 MBq
(15 mCi) of 131I-iodide. Six months after radioiodine therapy, under methimazole 40 mg, thyroid
stimulating hormone was 1.5 uIU/ml; free thyroxine 0.54 ng/dl. Methimazole was suspended. In
21 days, thyroid stimulating hormone was 0.03 uIU/ml; free thyroxine 0.96 ng/dl. Methimazole was
reintroduced. One year later, thyroid stimulating hormone was <0.01 uIU/ml and free
thyroxine >7.77 ng/dl. Thyroid 99mTc-pertechnetate uptake was 45% and estimated thyroid volume
144 mL. A 1110 MBq (30 mCi) radioiodine therpy was administered. He used Methimazole for
8 months, when overt hypothyroidism appeared (TSH: 25.30 uIU/ml; free thyroxine: 0.64 ng/dl).
Methimazole was interrupted. Hyperthyroidism returned 6 weeks later (thyroid stimulating
hormone <0.01 uIU/ml; free thyroxine >7.77 ng/dl). Thyroid 99mTc-pertechnetate uptake was 25%
and estimated thyroid volume 111 mL. Methimazole was prescribed again. In March 2008 he received
a 2590 MBq (70 mCi) radioiodine therapy. By may/2008, under methimazole 20 mg, his TSH was
0.07 uIU/ml; free thyroxine 1.31 ng/dl. In October 2008 he presented overt hypothyroidism (TSH
91.6 uIU/ml; free thyroxine 0.34) and was given levothyroxine 75 mcg/day. He remains euthyroid
under hormone replacement.
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Conclusion: Our presented case of Graves’ disease received a cumulative dose of 4255 MBq (115
mCi). The high uptake could indicate accelerated iodine turnover with 131I short time of action.
Impaired hormone synthesis could also be present. We believe the extremely high dose required was
due to the initial very high iodine uptake and large thyroid volume.
Introduction
Graves’ disease is the most common cause of hyperthyr-
oidism worldwide. The administration of radioactive
iodine (131I) has become widely prescribed for treatment
of this condition, because of both its safety and easiness of
use [1]. Much controversy has aroused as regard to the best
fixed dose sufficient to relieve the patient from hyperthyr-
oidism. Some authors advocate the use of higher doses,
intended to deliberately cause hypothyroidism soon after
treatment, and in so doing reduce the incidence of failure
and relapse. Usually, a dose of 370 to 555 MBq (10 to
15 mCi) is considered enough for this purpose [2], but
there are some reports of improved remission rates with
up to 740-1110 MBq (20-30 mCi) [3]. The majority of
patients require only a single dose and euthyroidism is
achieved in 6-8 weeks in 40 to 60% of them [4].Several
factors have been studied as outcome predictors in the use
of radioiodine therapy (RIT) for Graves’ disease, such as
sex, age, thyrotropin (TSH) and auto-antibodies levels,
thyroid volume and presence of ophthalmopathy [5].
Failure of RIT is mostly associated with larger goiter
volume or size, and some studies recommend that a
higher dose should be prescribed for these patients [6].
Generally, fewer than 10% of cases will require more than
one dose [7]. Similarly, recurrences are rare after a
hypothyroid state is achieved [8]. Reviewing the literature,
we found one report of a patient presenting relapse of
Graves’ hyperthyroidism 10 years after receiving a dose of
1424.5 MBq (38.5 mCi) [9], and none requiring more for
management of Graves’ disease.
Case presentation
We present the case of a, 53 years old male, Caucasoid
patient, attended at our Endocrinology service in Septem-
ber 2005, proceeding from an iodine sufficient area. His
main complaint was cervical enlargement for 2 years,
associated with weight loss (9 kg), tremors, palpitations
and fatigue. He denied any previous health conditions
such as hypertension or Diabetes Mellitus and was a non-
smoker. On physical examination he presented tachy-
cardia (130 bpm), an arrhythmic pulse and hypertension
(160 × 100 mmHg). Thyroid palpation revealed a large
goiter with firm consistency, smooth surface, preserved
mobility and no murmur on auscultation. There was no
apparent ophthalmopathy.
Laboratory tests showed: TSH:<0.01uIU/ml(0,41-4.5); FT4:
>7.77 ng/dl (0.9-1.8) and T3: >651 ng/dl (80-200).
Anti-thyreoperoxidase antibody: 374 IU/ml (<35); Anti-
thyreoglobulin antibody: 749 IU/ml (<115); Complete
Blood Count: White Blood Cells: 4030/mm3; Hemoglobin:
13.2 g/dl; Hematocrit: 38,1% and 219,000 platelets/mm3.
EKG demonstrated atrial fibrillation with a ventricular
response of approximately 140 bpm. Thyroid ultrasound
showed diffuse goiter with hypoechogenic parenchyma and
no nodules. Right lobe: 7.9 × 3.8 × 3.8 cm; left lobe 7.7 ×
3.5 × 3.8 cm; isthmus 1.6 cm. Transthoracic echocardiogram
revealed an ejection fraction (EF) of 61% with mild
enlargement of the left atrium and also mild incompet-
ence of all four cardiac valves. Estimated peak pulmonary
systolic pressure was 51 mmHg, compatible with mild
pulmonary hypertension. Therefore, the preliminary diag-
nosis was that of Grave’s disease with atrial fibrillation.
It was decided for admission in order to attain better
clinical management and close monitoring. Propylthio-
uracil (PTU) 300 mg t.i.d., along with propranolol and
warfarin were prescribed. During the patient’s stay there
was spontaneous reversion to sinus rhythm. He was
discharged 11 days later and in one month, October/2005,
received a 555 Mbq (15 mCi) oral dose of 131I. Thyroid
scan previous to radioiodine administration showed
diffuse goiter and a 99mTc-pertechnetate uptake of 52%
(0.35-1,7%). Using planar 99mTc-pertechnetate images,
thyroid volume estimated from this scan was 149 mL
(Figure 1). PTU was interrupted after the radioiodine
treatment (RIT) even though the patient was still
complaining of palpitations. Ten days later, laboratory
workup was: TSH: 0.01 uIU/ml; FT4: >7.77 ng/dl. He was
kept in use of propranolol 80 mg tid and methimazole
(MMI) 40 mg q.d. was initiated.
Six months after RIT, the patient’s TSH level was
1.5 uIU/ml; FT4 0.54 ng/dl and FT3 4.32 pg/ml (2.57-4.43).
MMI was suspended at this point, as the patient was
asymptomatic. Twenty days after discontinuation of
MMI, however, TSH was 0.03 uIU/ml, FT4 0.96 ng/dl and
FT3 0.51 ng/dl (0.257-0.443) and MMI was reintroduced.
One year after RIT, the patient relapsed into persistent
hyperthyroidism and second RIT was scheduled. TSH
was <0.01 uIU/ml, FT4 > 7.77 ng/dl and FT3 2.07 ng/dl.
Page 2 of 5
(page number not for citation purposes)
Cases Journal 2009, 2:8479 http://casesjournal.com/casesjournal/article/view/8479
A new thyroid scan demonstrated diffuse goiter and 45%
99mTc-pertechnetate uptake (estimated volume of 144
mL). Echocardiogram showed EF of 70% and mild mitral
and tricuspid regurgitation. A RIT of 1110 MBq (30 mCi)
was administered in February 2007. The patient was kept
in use of MMI until 8 months after the second RIT, when
he developed overt hypothyroidism (TSH: 25.30 uIU/ml;
FT4: 0.64 ng/dl). However, relapse of hyperthyroidism
occurred only 45 days after MMI withdrawal (TSH < 0.01
uIU/ml; FT4 > 7.77 ng/dl). A third scan was performed,
revealing 25% 99mTc-pertechnetate uptake (estimated
volume of 111 mL). Consequently, MMI was again
prescribed, and a third RIT planned.
In March 2008 he was admitted for 36 hours in order
to receive a dose of 2590 MBq (70 mCi) of 131I. Three
months later, the use of MMI 20 mg q.d. was still required
and his TSH level was 0.07 uIU/ml, FT4: 1.31 ng/dl and
FT3: 0.30 ng/dl.
In October 2008, his laboratory workup showed overt
hypothyroidism (TSH 91.6 uIU/ml and FT4 0.34). MMI
was withdrawal but hypothyroidism persisted and he was
therefore put on levothyroxine 75 mcg q.d. Six weeks later,
euthyroidism was restored (TSH: 0.51 uIU/ml and FT4:
1.78 ng/dl). He remains euthyroid with levothyroxine
replacement until the present date and no dose change was
required so far.
Discussion
Our presented case of Graves’ hyperthyroidism received a
cumulative 131I treatment of 4255 MBq (115 mCi). After
the first two RIT, the patient presented transient overt
hypothyroidism and rapidly relapsed into hyperthyroid-
ism after discontinuation of anti-thyroid therapy. Even
three months after the third higher dose, and in use of
20 mg of MMI, he remained with suppressed TSH levels.
Only five months after the last RIT would lasting
hypothyroid state manifest, requiring levothyroxine treat-
ment. We found no case reports in the literature of such a
high 131I requirement to control Graves’ disease.
Transient or definitive hypothyroidism after a radioiodine
dose is common, due to the acute injury to thyroid cells
and incapacitation to maintain the high hormone synth-
esis [10]. In addition, less than 15% of cases will relapse
into hyperthyroidism and require a second dose. The need
for more than two doses is even rarer [9].
The reason for the atypical behavior of this case can be at
least partially explained by the initial high 99mTc-
pertechnetate uptake found in the first scan. The radio-
pharmaceutical 99mTc-pertechnetate uptake reliably
reflects thyroid avidity for iodide. In Graves’ disease
there is an elevated clearance of plasma iodide and
increased thyroid peroxidase activity, leading to a higher
hormone synthesis. Therefore iodine turnover is faster and
consequently the residence time of radioiodine within the
gland is shorter. This could culminate in a reduced efficacy
of RIT (Figure 2) [11].
Supporting this hypothesis is also the very short period of
time during which the patient remained in hypothyroid-
ism following the first two RIT, possibly indicating a quick,
not sustained action of 131I on thyroid cells because of its
rapid turnover. Although not curative, they reduced
99mTc-pertechnetate uptake from 52% to 45%, and then
to 25%, making it more likely that another RIT would be
definitive and also demonstrating the partial effect of the
131I administered in these first two treatments. A very high,
2590 MBq (70 mCi) third RIT was then administered
hoping that a higher 131I dose would compensate for its
shorter time of action.
An impaired hormone synthesis could also be considered
to explain this very high uptake, but is much less likely
because of the high thyroid hormone levels at the time of
diagnosis and also throughout follow up.
Additionally, large goiters are associated with higher
incidence of failure and relapse [6] and maybe this is the
key factor in this case. When a fixed dose approach is used,
small and medium-sized glands have high and similar
cumulative incidence of hypothyroidism or euthyroidism
Figure 1. Patient’s first thyroid scan showing a
52% 99mTc-pertechnetate uptake and estimated volume
of 149 mL.
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following radioiodine treatment. Larger glands receiving
the same dose, however, tend to have a higher rate of
persistent hyperthyroidism after 1 year. The difference in
success rates is even more apparent in the first 6 months
[6]. Therefore for patients with larger goiter and higher
99mTc-pertechnetate uptakes, a calculated dose based on
size and uptake is perhaps a better decision [12]. Surgical
treatment (partial thyroidectomy) is also a reasonable
option in such cases, as it propitiates prompt relief of
symptoms related to compression of the esophagus and/or
trachea [13].
In the presented case, the first RIT with 555 MBq (15 mCi)
may not have been sufficient to cause complete ablation of
thyroid cells, because of the patient’s increased gland
volume. Residual cells viable and under continuous
stimulation of thyroid-stimulation immunoglobulin
could have caused recurrent hyperthyroidism. A similar
fact must have occurred after administration of the
1110 MBq (30 mCi) second RIT.
Conclusion
In conclusion, although the use of a fixed dose method
simplifies the approach to treatment with potential cost
savings, we believe that a higher dose of RIT should be
considered for patients with Graves’ disease presenting an
initial very high thyroid 99mTc-pertechnetate uptake. This
is especially true when high uptake is associated with
increased goiter size, as failure and relapse in such cases are
more likely to occur, leading to increased morbidity and
the need for further radiation exposure.
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